Phenylacetic acid compounds in treating abnormal platelet aggregation

A method of treating a condition exhibiting abnormal platelet aggregation which comprises the administration to humans and animals of a therapeutically effective amount of a compound having the formula:

• ##SPC9##
• or a pharmaceutically acceptable salt thereof, wherein
• R.sub..alpha. is hydrogen or methyl;
• R.sub.2, r.sub.3, x and Y are each hydrogen, chloro, bromo, or fluoro;
• and
• R.sub.4 is COOH;
• Coor, where R may be C.sub.1-5 alkyl, CONH.sub.2 ;
• or ##EQU3## where Y may be C.sub.1-3 alkyl.

A pharmaceutical composition comprising a pharmaceutical carrier and an effective non-toxic amount of 0.1 to 50 mg per kilogram of body weight of a compound of the formula:

• ##SPC13##
• or pharmaceutically acceptable salt thereof, wherein
• R.sub..alpha. is hydrogen or methyl:
• R'.sub..alpha. is hydrogen, or R.sub..alpha. and R'.sub..alpha. taken together can be methylene;
• or R'.sub..alpha. can be a methylene linkage attached to the unsubstituted ortho position of the benzenoid ring;
• X, y, r.sub.2 and R.sub.3 are the same or different and each is hydrogen, C.sub.1-5 alkyl, chloro, bromo, fluoro, and
• R.sub.4 is COOH, COOR, where R may be C.sub.1-5 alkyl, CONH.sub.2, ##EQU4## where Y may be C.sub.1-3 alkyl.

A pharmaceutical composition comprising a pharmaceutical carrier and an effective non-toxic amount of a compound of the formula:

• ##SPC15##
• or pharmaceutically acceptable salt thereof, wherein
• R.sub..alpha. is hydrogen or methyl;
• R.sub.2, r.sub.3, x and Y are each hydrogen, chloro, bromo, or fluoro;
• and
• R.sub.4 is COOH;
• COOR, where R may be C.sub.1-5 alkyl, CONH.sub.2 ;
• or ##EQU5## where Y may be C.sub.1-3 alkyl.